These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 23863877)

  • 1. Association of CYP2C9*2 with bosentan-induced liver injury.
    Markova SM; De Marco T; Bendjilali N; Kobashigawa EA; Mefford J; Sodhi J; Le H; Zhang C; Halladay J; Rettie AE; Khojasteh C; McGlothlin D; Wu AH; Hsueh WC; Witte JS; Schwartz JB; Kroetz DL
    Clin Pharmacol Ther; 2013 Dec; 94(6):678-86. PubMed ID: 23863877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2C9, SLCO1B1, SLCO1B3, and ABCB11 polymorphisms in patients with bosentan-induced liver toxicity.
    Roustit M; Fonrose X; Montani D; Girerd B; Stanke-Labesque F; Gonnet N; Humbert M; Cracowski JL
    Clin Pharmacol Ther; 2014 Jun; 95(6):583-5. PubMed ID: 24842639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic susceptibility to hepatoxicity due to bosentan treatment in pulmonary hypertension.
    Seyfarth HJ; Favreau N; Tennert C; Ruffert C; Halank M; Wirtz H; Mössner J; Rosendahl J; Kovacs P; Wittenburg H
    Ann Hepatol; 2014; 13(6):803-9. PubMed ID: 25332267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing the risk of drug-induced liver injury.
    Watkins PB
    Clin Pharmacol Ther; 2013 Dec; 94(6):629-31. PubMed ID: 24241638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers.
    Markert C; Burhenne J; Weiss J; Mikus G; Haefeli WE
    Clin Pharmacol Ther; 2014 Mar; 95(3):250-1. PubMed ID: 24048276
    [No Abstract]   [Full Text] [Related]  

  • 6. Response to "CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers".
    Markova SM; Schwartz JB; Kroetz DL
    Clin Pharmacol Ther; 2014 Mar; 95(3):252. PubMed ID: 24346422
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetics of bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension.
    Taguchi M; Ichida F; Hirono K; Miyawaki T; Yoshimura N; Nakamura T; Akita C; Nakayama T; Saji T; Kato Y; Horiuchi I; Hashimoto Y
    Drug Metab Pharmacokinet; 2011 Jun; 26(3):280-7. PubMed ID: 21383523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.
    Treiber A; Schneiter R; Häusler S; Stieger B
    Drug Metab Dispos; 2007 Aug; 35(8):1400-7. PubMed ID: 17496208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI).
    Pachkoria K; Lucena MI; Ruiz-Cabello F; Crespo E; Cabello MR; Andrade RJ;
    Br J Pharmacol; 2007 Mar; 150(6):808-15. PubMed ID: 17279092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An atypical presentation of liver enzyme elevation resulting from bosentan use.
    Mulchey K; Bshouty Z
    Can Respir J; 2009; 16(5):e54-6. PubMed ID: 19851530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers.
    Cheng Y; Wang G; Zhang W; Fan L; Chen Y; Zhou HH
    Eur J Clin Pharmacol; 2013 Mar; 69(3):407-13. PubMed ID: 22842957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined use of ursodeoxycholic acid and bosentan prevents liver toxicity caused by endothelin receptor antagonist bosentan monotherapy: two case reports.
    Ito T; Ozaki Y; Son Y; Nishizawa T; Amuro H; Tanaka A; Tamaki T; Nomura S
    J Med Case Rep; 2014 Jul; 8():250. PubMed ID: 25015229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers.
    Markert C; Schweizer Y; Hellwig R; Wirsching T; Riedel KD; Burhenne J; Weiss J; Mikus G; Haefeli WE
    Br J Clin Pharmacol; 2014 Jan; 77(1):141-8. PubMed ID: 23738582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability of Switch to Macitentan from Bosentan in Pulmonary Arterial Hypertension.
    Safdar Z; Thakur A; Frost A
    South Med J; 2017 Mar; 110(3):223-228. PubMed ID: 28257550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the Metabolic Pathway of Bosentan and of the Cytotoxicity of Bosentan Metabolites Based on a Quantitative Modeling of Metabolism and Transport in Sandwich-Cultured Human Hepatocytes.
    Matsunaga N; Kaneko N; Staub AY; Nakanishi T; Nunoya K; Imawaka H; Tamai I
    Drug Metab Dispos; 2016 Jan; 44(1):16-27. PubMed ID: 26502773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.
    Dingemanse J; van Giersbergen PL
    Clin Pharmacokinet; 2004; 43(15):1089-115. PubMed ID: 15568889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The drug-drug interaction potential of rifampicin.
    Srinivas NR
    Clin Ther; 2008 Oct; 30(10):1932-3. PubMed ID: 19014849
    [No Abstract]   [Full Text] [Related]  

  • 18. Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers.
    Werner D; Werner U; Meybaum A; Schmidt B; Umbreen S; Grosch A; Lestin HG; Graf B; Zolk O; Fromm MF
    Clin Pharmacokinet; 2008; 47(5):323-32. PubMed ID: 18399713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli.
    Spangler ML; Saxena S
    Clin Ther; 2010 Jan; 32(1):53-6. PubMed ID: 20171411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics.
    Vormfelde SV; Toliat MR; Schirmer M; Meineke I; Nürnberg P; Brockmöller J
    Clin Pharmacol Ther; 2008 Jun; 83(6):815-7. PubMed ID: 18043684
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.